News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

ProMetic Life Sciences Inc. (PFSCF.PK): Lancet Study Reports 'Significant Breakthrough' In Quest To Prevent vCJD Transmission Through Blood Tranfusion



12/22/2006 11:30:52 AM

CAMBRIDGE, UNITED KINGDOM AND LILLE, FRANCE -- (MARKET WIRE) -- December 21, 2006 -- Pathogen Removal and Diagnostic Technologies Inc. (PRDT), a joint-venture between ProMetic Life Sciences Inc. (TSX: PLI) ("ProMetic") and The American Red Cross (ARC), along with PRDT's co-development, commercial and manufacturing partner, MacoPharma, announce that a study published today in the Lancet (Gregori L, Gurgel P, Lathrop J et al) reveals that PRDT's prion capture affinity resin incorporated into the P-CAPTĀ® prion capture filter removes, to the limit of detection, the infectivity that is naturally present in blood during infections by Transmissible Spongiform Encephalopathies (TSE's), such as variant Creutzfeldt-Jakob disease (vCJD) and that it prevents the transmission of infection by contaminated blood.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES